Abstract
Tuberculosis (TB) is a global problem and the spread of multi-drug-resistant (MDR) TB, defined as resistance to at least isoniazid and rifampicin, is a formidable challenge for control programs. There are no widely accepted standard regimens for the treatment of MDR-TB. However, a considerable proportion of cases can be cured with a regimen containing both first-line and second-line drugs. In order to prevent the development of resistance to drugs already in use and also to try to develop a standard regimen, there is need to look for new drugs. This review is prepared to show results on the anti-TB activity of -lactam antibiotics. -Lactams are among the oldest drugs with little or no side effects. Both in vitro studies and clinical data indicate that -lactams have a promising activity for use in the management of MDR-TB. More studies are required to define the interaction of -lactams with other first-line and second-line drugs, and to clearly show the clinical usefulness in the management of MDR-TB. (Ethiopian Journal of Health Development, 2000, 14(3): 269-276)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
